Pfizer considers antiviral options as Paxlovid use skyrockets amid worries of resistance
When Pfizer’s Covid-19 antiviral Paxlovid first hit the shelves last December, it was widely seen as the best option to keep those at high risk of hospitalization out of the hospital.
But that early caution with regard to who received the pill has generally been thrown into the wind as almost a million Americans per month (or about 1 in every 4 officially reported Covid-19 case) now uses the antiviral, according to the latest US government data. The spike in usage comes as pharmacists are now allowed to offer Paxlovid in the US, and as Pfizer begins to weigh its options with regard to combo treatments and a second-generation antiviral.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.